A new study has addressed a key question in autosomal dominant polycystic kidney disease (ADPKD): can we predict renal outcome at an early disease stage? Indeed, this information is useful for any patient with ADPKD. Moreover, while targeted therapies continue to emerge, optimal selection of patients for clinical trials remains a challenge.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grantham, J. J. et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122–2130 (2006).
Chapman, A. B. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 479–486 (2012).
Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2013101138.
Mayo Foundation for Medical Education and Research. Classification of Typical ADPKD Calculator [online].
Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830–840 (2010).
Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820–829 (2010).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Caroli, A. et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382, 1485–1495 (2013).
Cornec-Le Gall, E. et al. Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol. 24, 1006–1013 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.C. L.G. declares that she has received travel grants from Otsuka and Roche. Y.L.M. declares that he has received research funding, honoraria for speaking and travel grants from Astellas, Chiesi, Novartis, Otsuka, Roche and Sanofi.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Cornec-Le Gall, E., Le Meur, Y. Kidney volume—a crystal ball for ADPKD prognosis?. Nat Rev Nephrol 10, 485–486 (2014). https://doi.org/10.1038/nrneph.2014.132
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.132
This article is cited by
-
Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients
BMC Nephrology (2017)
-
HALTing PKD progression—revival of blood pressure control
Nature Reviews Nephrology (2015)
